VANCOUVER, Washington, July 29, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
39% of Patients in Placebo Arm Had SAEs as Compared to Only 14% of Patients in Leronlimab Arm Had SAEs,
Read more
This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of
Read more
VANCOUVER, Washington, July 02, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company
Read more
VANCOUVER, Washington, June 29, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
If granted, the FDA is expected to take action on the Company’s BLA within six months VANCOUVER, Washington, June 01,
Read more
VANCOUVER, Washington, May 18, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
CytoDyn Submits Requested Datasets to FDA for Biologics License Application VANCOUVER, Washington, May 13, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB:
Read more
VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far VANCOUVER, Washington, April 30, 2020
Read more
VANCOUVER, Washington, April 15, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more
VANCOUVER, Washington, April 09, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing
Read more